Globus Medical (GMED) to Release Quarterly Earnings on Thursday

Globus Medical (NYSE:GMED - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 8th. Analysts expect Globus Medical to post earnings of $0.74 per share and revenue of $629.74 million for the quarter.

Globus Medical (NYSE:GMED - Get Free Report) last released its earnings results on Thursday, February 20th. The medical device company reported $0.84 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.10. The company had revenue of $657.29 million during the quarter, compared to analysts' expectations of $646.19 million. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. On average, analysts expect Globus Medical to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Globus Medical Stock Performance

GMED stock traded up $0.79 during midday trading on Friday, reaching $71.90. The stock had a trading volume of 1,182,627 shares, compared to its average volume of 1,045,389. The firm has a fifty day simple moving average of $73.33 and a two-hundred day simple moving average of $80.04. The stock has a market cap of $9.89 billion, a PE ratio of 95.87, a P/E/G ratio of 1.61 and a beta of 1.32. Globus Medical has a 52-week low of $50.00 and a 52-week high of $94.93.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Truist Financial dropped their price objective on shares of Globus Medical from $82.00 to $80.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of Globus Medical in a report on Tuesday, March 18th. StockNews.com downgraded shares of Globus Medical from a "buy" rating to a "hold" rating in a report on Friday, March 21st. Barclays increased their price target on Globus Medical from $100.00 to $103.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Finally, Wells Fargo & Company reduced their target price on Globus Medical from $95.00 to $93.00 and set an "overweight" rating for the company in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $96.91.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.